IP Library Patent Application 18414854
Patent Application
App. No. 18/414,854

OPHTHALMIC DEVICES HAVING A HIGH REFRACTIVE INDEX AND ABBE NUMBER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/414,854
Abstract

An ophthalmic device which is a polymerization product of a monomeric mixture includes (a) from about 30 to about 75 weight percent, based on the total weight of the monomeric mixture, of one or more cycloaliphatic (meth)acrylic monomers; (b) greater than about 25 weight percent, based on the total weight of the monomeric mixture, of one or more hydrophilic monomers; and (c) one or more crosslinking agents, wherein the ophthalmic device has a refractive index of about 1.48 to about 1.52 and an Abbe number greater than or equal to 50.

Claims (33)

1 . An ophthalmic device which is a polymerization product of a monomeric mixture comprising:

(a) from about 15 to about 75 weight percent, based on the total weight of the monomeric mixture, of one or more cycloaliphatic (meth)acrylic monomers;

(b) greater than 25 weight percent, based on the total weight of the monomeric mixture, of one or more hydrophilic monomers; and

(c) one or more crosslinking agents;

wherein the ophthalmic device has a refractive index of about 1.48 to about 1.52 and an Abbe number greater than or equal to 50.

2 . The ophthalmic device according to claim 1 , wherein the one or more cycloaliphatic (meth)acrylic monomers comprise one or more monocyclic cycloaliphatic (meth)acrylic monomers.

3 . The ophthalmic device according to claim 2 , wherein the one or more monocyclic cycloaliphatic monomers comprise a C 3 -C 8 cycloalkyl group and a (meth)acrylic group.

4 . The ophthalmic device according to claim 3 , wherein the (meth)acrylic group is (meth)acrylate-containing reactive end groups.

5 . The ophthalmic device according to claim 1 , wherein the one or more cycloaliphatic (meth)acrylic monomers are represented by a structure of formula I:

wherein x is an integer from 0 to 9; y is an integer from 0 to 3; B is O, NR, or S, where R is H, CH 3 , CH 2 CH 3 , or CH(CH 3 ) 2 ; D is O, S, or a bond; A is H or CH 3 ; and z is 0 to 4, provided that if D is a bond then at least one of y and z is 0.

6 . The ophthalmic device according to claim 5 , wherein x is an integer from 1 to 4; y is 0; D is O; z is an integer from 1 to 4; B is O; and A is H or CH 3 .

7 . The ophthalmic device according to claim 5 , wherein x is an integer from 1 to 4; y is an integer from 1 to 4; D is a bond; z is 0; B is O; and A is H or CH 3 .

8 . The ophthalmic device according to claim 1 , wherein the one or more hydrophilic monomers are selected from the group consisting of an unsaturated carboxylic acid, an acrylamide, a vinyl lactam, a hydroxyl-containing-(meth)acrylate, a hydrophilic vinyl carbonate, a hydrophilic vinyl carbamate monomer, a hydrophilic oxazolone monomer, and mixtures thereof.

9 . The ophthalmic device according to claim 1 , wherein the one or more hydrophilic monomers are one or more of 2-hydroxyethyl methacrylate and N,N-dimethylacrylamide.

10 . The ophthalmic device according to claim 1 , wherein the one or more hydrophilic monomers comprise from greater than 25 weight percent to about 40 weight percent, based on the total weight of the monomeric mixture, and the one or more crosslinking agents comprise from about 1 weight percent to about 10 weight percent, based on the total weight of the monomeric mixture.

11 . The ophthalmic device according to claim 1 , wherein the one or more crosslinking agents are selected from the group consisting of 1,4-butanediol diacrylate, 1,4-butanediol dimethacrylate, ethylene glycol dimethacrylate, diethylene glycol) diacrylate, diethylene glycol) dimethacrylate, triethylene glycol diacrylate, triethylene glycol dimethacrylate, tetraethylene glycol diacrylate, tetraethylene glycol dimethacrylate, 1,3-propanediol diacrylate, 1,3-propanediol dimethacrylate, 1,6-hexanediol diacrylate, 1,6-hexanediol dimethacrylate, poly(ethylene glycol) diacrylate, poly(ethylene glycol) dimethacrylate, and poly(ethylene glycol) dimethacrylate.

12 . The ophthalmic device according to claim 1 , wherein the one or more crosslinking agents comprise from about 3 weight percent to about 5 weight percent, based on the total weight of the monomeric mixture, of ethylene glycol dimethacrylate.

13 . The ophthalmic device according to claim 1 , wherein the monomeric mixture comprises:

(a) from about 30 to about 75 weight percent, based on the total weight of the monomeric mixture, of one or more cycloaliphatic (meth)acrylic monomers;

(b) greater than 25 and up to about 40 weight percent, based on the total weight of the monomeric mixture, of one or more hydrophilic monomers; and

(c) from about 1 to about 10 weight percent, based on the total weight of the monomeric mixture, of one or more crosslinking agents.

14 . The ophthalmic device according to claim 1 , wherein the monomeric mixture further comprises one or more of a reactive ultraviolet absorber and a reactive blue-light absorber.

15 . The ophthalmic device according to claim 1 , wherein the monomeric mixture further comprises one or more C 3 to C 12 aliphatic (meth)acrylate monomers.

16 . The ophthalmic device according to claim 1 , wherein the ophthalmic device has a Tg of less than 25° C.

17 . The ophthalmic device according to claim 1 , wherein the ophthalmic device has an equilibrium water content (EWC) of greater than 2% and up to 9%.

18 . The ophthalmic device according to claim 1 , wherein the ophthalmic device is a thermally cured polymerization product.

19 . The ophthalmic device according to claim 1 , wherein the ophthalmic device is an intraocular lens.

20 . A method for making an ophthalmic device, comprising:

(a) providing a monomeric mixture comprising:

(i) from about 15 to about 75 weight percent, based on the total weight of the monomeric mixture, of one or more cycloaliphatic (meth)acrylic monomers;

(ii) greater than 25 weight percent, based on the total weight of the monomeric mixture, of one or more hydrophilic monomers; and

(iii) one or more crosslinking agents; and

(b) subjecting the monomeric mixture to polymerization conditions to provide an ophthalmic device having a refractive index of about 1.48 to about 1.52 and an Abbe number greater than or equal to 50.

Assignments (5)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (067501/0955) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0665 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 23, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 067527/0251 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 22, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 067501/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2024
From: LAREDO, WALTER; ZHANG, BORUI; LINHARDT, JEFFREY
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 066161/0371 →